Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - carbidopa, levodopa - tablet - carbidopa 10.8 mg levodopa 100 mg - anti-parkinson drugs

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - carbidopa, levodopa - tablet - carbidopa 27 mg levodopa 100 mg - anti-parkinson drugs

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levodopa, carbidopa - tablet - levodopa 27 mg carbidopa 250 mg - anti-parkinson drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

roche products limited - levodopa, benserazide hydrochloride - tablets - 100/25 milligram - dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

roche products limited - levodopa, benserazide hydrochloride - tablets - 50/12.5 milligram - dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

roche products limited - levodopa, benserazide hydrochloride - capsules hard - 200/50 milligram - dopa and dopa derivatives

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - indications and usage: carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. contraindications: nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least 2 weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hydrochloride) (see precautions: drug interactions ).     carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma.

Malta - English - Medicines Authority

hospira uk limited - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.